Status:

SUSPENDED

Resting Energy Expenditure in Patients With OHS Treated With Long-term NIV

Lead Sponsor:

University Hospital, Geneva

Conditions:

Obesity-hypoventilation Syndrome

Resting Energy Expenditure

Eligibility:

All Genders

18-100 years

Brief Summary

This study aims to compare, in subjects with obesity-hypoventilation syndrome (OHS) treated by long-term non-invasive ventilation (NIV), resting energy expenditure (REE) in spontaneous breathing and u...

Detailed Description

This is an observational monocentric study in which each subject will be its own control. Patients' resting energy expenditure will be measured at rest ("spontaneous breathing" condition) and under it...

Eligibility Criteria

Inclusion

  • Fulfill all criteria of obesity hypoventilation syndrome.
  • Under home NIV for at least 3 months.
  • Are compliant to their treatment of NIV (defined as a daily median use \> 3:30 hours).
  • Have a satisfactory response to NIV (defined by a daytime PaCO2 in a sitting position \< 6.5 kPa, and a mean nocturnal SpO2 \> 90%, with less than 20% of total recording time spent with an SpO2 \< 90%).
  • Are in a stable clinical condition (i.e. no episode of acute cardiac and/or respiratory failure leading to a hospitalization within the preceding 3 months).
  • Are over 18 years of age.
  • Are able to provide informed consent.
  • Agree to participate in the study.

Exclusion

  • Presents any respiratory disorder other than OHS.
  • Has been under NIV less than 3 months.
  • Is noncompliant (defined above) and/or intolerant to NIV.
  • NIV not reaching the above-mentioned physiological targets (defined by a daytime PaCO2 in a sitting position \< 6.5 kPa, and a mean nocturnal SpO2 \> 90%, with less than 20% of total recording time spent with an SpO2 \< 90%).
  • Had a recent episode of cardiac and/or respiratory failure leading to a hospitalization within the preceding 3 months.
  • Is under 18 years of age.
  • Presents a situation interfering with understanding of the protocol and ability to provide informed written consent (language barrier, cognitive disorder, psychiatric disturbance).
  • Refuses to participate in the study.
  • Is under nocturnal oxygen supplementation on NIV.

Key Trial Info

Start Date :

September 1 2020

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 1 2022

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT04474587

Start Date

September 1 2020

End Date

December 1 2022

Last Update

November 8 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Geneva University Hospital

Geneva, Switzerland, 1205